NMS 0963
Alternative Names: NMS-0963Latest Information Update: 07 Jun 2023
At a glance
- Originator Nerviano Medical Sciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diffuse large B cell lymphoma
Most Recent Events
- 14 Apr 2023 Pharmacodynamics, pharmacokinetics and adverse events data from a preclinical study in Diffuse large B cell lymphoma presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023 (3791461)
- 05 Apr 2023 Preclinical trials in Diffuse large B cell lymphoma in Italy (PO)
- 05 Apr 2023 Nerviano Medical Sciences plans a clinical trial for Diffuse large B-cell lymphoma (DLBCL)